Developing switchable bispecific T-cell engagers to fight cancer Who we are We are an immuno-oncology company developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives. LEARN MORE Our technology Our pioneering...
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $42M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| 12.06.2021 | 5AM Ventur... | 5amventure... |
| 22.08.2022 | MBC BioLab... | mbcbiolabs... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.05.2021 | Series A | $42M | 5AM Ventur... |
Mentions in press and media 3
| Date | Title | Description |
| 20.05.2021 | Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures | SAN FRANCISCO, May 17, 2021: Soteria Biotherapeutics, Inc. ("Soteria"), a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor ... |
| 17.05.2021 | Soteria Biotherapeutics : Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures | SAN FRANCISCO, May 17, 2021 /PRNewswire/ -- Soteria Biotherapeutics, Inc. ("Soteria"), a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients wi... |
| 17.05.2021 | Soteria Biotherapeutics Raises $42M in Series A Financing | Soteria Biotherapeutics, Inc., a San Francisco, CA-based immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, raised $42m in Series A financing.... |